Entries by Annette Säfholm

BioStock publishes updated analysis of Idogen

BioStock has yesterday, the 12th of September 2017, published an updated analysis of Idogen. The analysis is now available on BioStock’s and Idogen’s websites (www.biostock.se, www.idogen.com). On behalf of Idogen, Biostock has analyzed the company’s project portfolio and will continue to follow the company.   Extract from BioStock’s analysis: “Idogens present market cap or around […]

Idogen participates in large Vinnova-initiative to make Sweden a leader in biological medicines

Idogen AB (”Idogen”) is a partner in a Vinnova project, awarded in total 48 million SEK in grants to run the cell and gene therapy project CAMP – Centre for Advanced Medical Products. Idogen will collaborate with, among others, AstraZeneca, GE Healthcare, Pfizer, all Swedish universities, several health care regions and research institutions to create […]

BioStock publishes analysis of Idogen

Today, June 2 2017, BioStock has published an analysis of Idogen. The analysis is now available on BioStock’s, Idogen’s and Redeye’s respective websites (www.biostock.se, www.idogen.com, http://beta.redeye.se/transaction/idogen). On behalf of Idogen, Biostock has analyzed the company’s project portfolio and will continue to follow the company for one year.   Extract from BioStock’s analysis: “BioStock has analyzed […]

Idogen has been granted EUR 2.9 million funding from Horizon 2020

Idogen AB (“Idogen”) today announces that the company has been awarded funding of 2.9 million Euro from Horizon 2020, the EU Framework Programme for Research and Innovation, for the development of the company’s tolerogenic vaccine for the treatment of patients with severe hemophilia A and inhibitory antibodies against factor VIII.   The EU Horizon 2020 […]

Tolerogenic vaccine for kidney transplantation to be next therapeutic area for Idogen

Idogen AB (”Idogen”) today announces that the company has decided that solid organ transplantation will be its next therapeutic area. The company has adopted a progressive development strategy in which a tolerogenic vaccine for kidney transplantation will be developed in parallel with the first tolerogenic vaccine for the treatment of inhibiting anti-factor VIII antibodies in […]

Idogen decides on in-house production of tolerogenic vaccine

Idogen AB (“Idogen”) today announced that it has entered into an agreement with Medicon Village AB for use of custom cleanroom in order to produce the company’s cell therapy products for future clinical studies. The agreement means that Idogen get control over the production of its therapeutic vaccine for the first clinical studies. That the […]

Idogen recruits Chief Medical Officer

Idogen AB (”Idogen”) announces that it has recruited Dr. Steven Glazer to the position of Chief Medical Officer (CMO) commencing the 1st of April. This appointment means a significant strengthening of the organization for future clinical studies, initially in hemophilia A. Steven Glazer’s most recent role was as CMO at Hansa Medical AB, listed on […]